This is still a speculative stock, but the Clemson professor behind Prolanta has a history of success. And...with the backing off Komen Foundation, who knows how high Oncolix will climb. I think once fully approved, $30 is not unreasonable, but that is years away.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.